| __timestamp | Catalyst Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 11606000000 |
| Thursday, January 1, 2015 | 8597010 | 10313000000 |
| Friday, January 1, 2016 | 7910260 | 9762000000 |
| Sunday, January 1, 2017 | 7304399 | 9830000000 |
| Monday, January 1, 2018 | 15875961 | 10102000000 |
| Tuesday, January 1, 2019 | 36881187 | 10615000000 |
| Wednesday, January 1, 2020 | 44233754 | 8955000000 |
| Friday, January 1, 2021 | 49628000 | 9634000000 |
| Saturday, January 1, 2022 | 58183000 | 10042000000 |
| Sunday, January 1, 2023 | 133710000 | 10504000000 |
Data in motion
In the world of pharmaceuticals, operational efficiency is key. Over the past decade, Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have remained relatively stable, fluctuating around $10 billion annually. In contrast, Catalyst Pharmaceuticals has seen a dramatic increase, with expenses rising nearly 30 times from 2014 to 2023. This surge reflects Catalyst's aggressive expansion and investment in growth. By 2023, Catalyst's SG&A expenses reached approximately 1.3% of Merck's, highlighting the scale difference between the two. This analysis underscores the diverse strategies employed by pharmaceutical giants and emerging players in managing operational costs.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights